Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk to cut 9,000 jobs in major restructuring drive
02:52am, Wednesday, 10'th Sep 2025
Novo Nordisk (NYSE:NVO) has announced plans to reduce its global workforce by around 9,000 roles, roughly 12% of its 78,400 employees, as part of a wide-ranging company overhaul aimed at sharpening f
Wegovy-maker Novo Nordisk to cut 9,000 jobs in restructuring
02:43am, Wednesday, 10'th Sep 2025
The company, which is also known for its Ozempic diabetes treatment, already said in August that it had implemented a global hiring freeze covering job roles that were not critical for its business.
Wegovy-maker Novo Nordisk to cut around 9,000 jobs
01:18am, Wednesday, 10'th Sep 2025
5,000 of the job cuts are expected in Denmark.
Novo Nordisk to cut 9,000 jobs in restructuring
01:07am, Wednesday, 10'th Sep 2025
Wegovy-maker Novo Nordisk will cut 9,000 jobs in a restructuring, aiming to save 8 billion Danish crowns ($1.26 billion) annually, the company said on Wednesday, as it battles rising pressure from mai
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Tuesday, 09'th Sep 2025
LOS ANGELES , Sept. 9, 2025 /PRNewswire/ -- The Law Offices of Frank R.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
10:46am, Tuesday, 09'th Sep 2025
NEW YORK--(BUSINESS WIRE)---- $NVO #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo Nordisk” or the “
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Tuesday, 09'th Sep 2025
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
1 Reason Every Investor Should Know About Novo Nordisk (NVO)
09:00pm, Monday, 08'th Sep 2025
It's no secret that Novo Nordisk (NVO -1.72%) and Eli Lilly (LLY 1.52%) are toughing it out in the battle of the weight loss drug market. It's also not lost on many investors that Eli Lilly's obesity
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit – NVO
04:17pm, Monday, 08'th Sep 2025
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
10:28am, Monday, 08'th Sep 2025
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) investors o
Ozempic Is The New Botox And Big Pharma Is Printing Billions
10:18am, Monday, 08'th Sep 2025
Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S NVO and Eli Lilly And Co LLY achieve a combined market cap topping $900 billion. Celebrit
Novo Nordisk: A Pharma Leader With Growth Potential And Portfolio-Defensive Appeal
09:58am, Monday, 08'th Sep 2025
Novo Nordisk is a strong buy, driven by its leading position in diabetes and obesity, robust fundamentals, and significant growth potential. The company's main revenue stream—GLP-1 drugs for diabete
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - NVO
08:45am, Monday, 08'th Sep 2025
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
